Wilmington Savings Fund Society FSB Has $3.87 Million Stock Holdings in Royalty Pharma PLC $RPRX

Wilmington Savings Fund Society FSB cut its position in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 1.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 107,448 shares of the biopharmaceutical company’s stock after selling 1,428 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Royalty Pharma were worth $3,871,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Louisbourg Investments Inc. bought a new position in Royalty Pharma during the first quarter worth about $28,000. USA Financial Formulas bought a new position in Royalty Pharma during the second quarter worth about $32,000. Summit Securities Group LLC bought a new position in Royalty Pharma during the first quarter worth about $36,000. WPG Advisers LLC bought a new position in Royalty Pharma during the first quarter worth about $39,000. Finally, Allworth Financial LP lifted its stake in Royalty Pharma by 41.6% during the first quarter. Allworth Financial LP now owns 1,539 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 452 shares during the period. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Stock Performance

RPRX stock opened at $36.00 on Wednesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.26 and a quick ratio of 1.26. The company has a 50 day moving average price of $36.09 and a 200 day moving average price of $34.71. Royalty Pharma PLC has a fifty-two week low of $24.05 and a fifty-two week high of $38.00. The stock has a market capitalization of $20.99 billion, a PE ratio of 20.81, a price-to-earnings-growth ratio of 1.95 and a beta of 0.60.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.04. Royalty Pharma had a net margin of 44.23% and a return on equity of 25.54%. The firm had revenue of $578.67 million during the quarter, compared to analysts’ expectations of $750.06 million. Analysts forecast that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were given a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 2.4%. The ex-dividend date was Friday, August 15th. Royalty Pharma’s payout ratio is 50.87%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on RPRX. Morgan Stanley cut their price target on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating for the company in a research note on Friday. Weiss Ratings upgraded shares of Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Citigroup raised their price target on shares of Royalty Pharma from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, July 22nd. The Goldman Sachs Group began coverage on shares of Royalty Pharma in a research note on Tuesday, September 30th. They set a “buy” rating and a $42.00 price target for the company. Finally, Wall Street Zen cut shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research note on Saturday, September 13th. One equities research analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $46.00.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.